Infusion therapy

BD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System

Retrieved on: 
Friday, July 21, 2023
Partnership, EMR, BD (company), Food, COVID, Infusion therapy, Becton, Dickinson and Company headquarters, PCA, Hospital, Investment, Patient, Nursing, PCU, Growth, Becton, EPS, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, BDX, NYSE, Caregiver, Safety, BD, Software, Medical device, Computer data storage, Alaris

"The 510(k) clearance of the updated BD Alaris™ Infusion System has been the number one priority for our teams who have been steadfast in their efforts to achieve this milestone, consistent with our commitment to quality," said Tom Polen, chairman, CEO and president of BD.

Key Points: 
  • "The 510(k) clearance of the updated BD Alaris™ Infusion System has been the number one priority for our teams who have been steadfast in their efforts to achieve this milestone, consistent with our commitment to quality," said Tom Polen, chairman, CEO and president of BD.
  • "We are deeply committed to ensuring clinicians can continue to rely on our market leading system to meet today's most critical infusion needs.
  • "Today, a majority of hospitals in the United States use the BD Alaris™ Infusion System to safely deliver IV therapies to patients, and this comprehensive clearance provides a foundation to support a steady, reliable cadence of innovation in infusion technologies from BD.
  • For more information on the BD Alaris™ Infusion System, visit: https://www.bd.com/en-us/products-and-solutions/products/product-brands/... .

Wellbeing Subsidiary Mindscape Treats its 1,000th Patient

Retrieved on: 
Tuesday, November 29, 2022
Alternative Medicine, Mental Health, Health, Other Health, Clinical Trials, Biotechnology, Mental health, NEO, Well-being, OTC, SQ2, Bipolar disorder, Clinic, Life, Emergency physician, Chronic pain, Patient, Anxiety, Drug development, Depression, Ketamine, PLLC, Mindscape, Digital Science, Therapy, PTSD, Infusion therapy, IV, OCD, MEDI, FRA, Acquisition, Pharmaceutical industry

Today, Mindscape aims to help facilitate patient healing using low-dose IV ketamine treatments.

Key Points: 
  • Today, Mindscape aims to help facilitate patient healing using low-dose IV ketamine treatments.
  • The Clinic reached the patient milestone in less than two years since its acquisition by Wellbeing, demonstrating the great need for this breakthrough treatment.
  • "In addition to the Clinics remarkable efficiency and reduction in treatment times, the clinical advantages of IV Ketamine therapy have also become increasingly evident, said Najla Guthrie, CEO of Wellbeing Digital Sciences.
  • Subsidiary of Wellbeing Digital Sciences, Mindscape Ketamine & Infusions Therapy, PLLC is a clinic in Houston, Texas, offering affordable delivery of concierge IV ketamine therapy for treatment-resistant mood disorders, mental health disorders, and chronic pain conditions.

Wellbeing Digital Sciences Welcomes Dr. Michael Ho as New Medical Director of MindScape Clinic in Houston

Retrieved on: 
Tuesday, May 3, 2022
Bipolar disorder, Anesthesiology, MEDI, Drug development, Washington University School of Medicine, Department, University, Clinic, GLOBE, SQ2, Company, Ketamine, Baylor University, Moses Austin, Depression, Mindscape, Consultant, Mindscape (company), Well-being, NEO, Anesthesia, Patient, Infusion, George Washington University School of Medicine & Health Sciences, Infusion therapy, OTC, FRA, Hospital, Therapy, Anxiety, Education, Retirement, Publication, University of Texas Medical Branch, PTSD, Baylor College of Medicine, Chronic pain, IV, Medical director, OCD, Cornell University, Pediatrics, Emergency physician, PLLC, Lists of diseases, Bipolar, Medical device, Pharmaceutical industry, Biochemistry

MindScapes former medical director, Dr. Quang Henderson, is retiring after his tenure since founding the Clinic in 2018.

Key Points: 
  • MindScapes former medical director, Dr. Quang Henderson, is retiring after his tenure since founding the Clinic in 2018.
  • Dr. Michael Ho serves as the director of Safe Sleep Anesthesia in Houston, Texas.
  • He is also the course director of Anesthesiology Consultants in Houston, Texas, with an accumulation of over 20,000 hours of anesthesia instruction to his credit.
  • Wellbeing is in the process of evaluating the addition of complementary mental health services being provided to patients at the Clinic.

Fresenius Kabi Announces FDA Approval of SMOFlipid® Lipid Injectable Emulsion for Pediatric Patients Requiring Parenteral Nutrition

Retrieved on: 
Thursday, March 24, 2022
Medical Devices, Medical Supplies, FDA, Children, Fitness & Nutrition, Other Health, Health, Consumer, Pharmaceutical, Parenteral nutrition, Lipid, Human, Fresenius (company), Glucose, Oil, Neck, ASPEN, Electrolyte, Organic acid, Multimedia, MCT, Adult, Medical Affairs Bureau, Route of administration, Administration, Olive oil, Pediatrics, ILE, Light, ESPEN, Infusion therapy, Vitamin, Fats, Maximal and minimal elements, Gastrointestinal tract, Iles, FDA, Carbohydrate, Patient, Pharmaceutical industry, Dietary supplement, Dentistry

Fresenius Kabi announced today it has been granted an expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.1 SMOFlipid can be used throughout the continuum of care from the hospital to home care settings.

Key Points: 
  • Fresenius Kabi announced today it has been granted an expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.1 SMOFlipid can be used throughout the continuum of care from the hospital to home care settings.
  • View the full release here: https://www.businesswire.com/news/home/20220324005347/en/
    SMOFlipid Lipid Injectable Emulsion, now FDA approved for pediatric patients requiring parenteral nutrition.
  • (Graphic: Business Wire)
    The FDA approval of SMOFlipid for pediatric patients represents an important expansion of our parenteral nutrition portfolio and our continued commitment to providing innovative nutrition products to our clinical partners and the patients they serve, said Gordon Sacks, PharmD., senior director Medical Affairs, Fresenius Kabi USA.
  • Being able to meet these needs now with SMOFlipid for pediatric patients demonstrates our dedication to innovation when it comes to helping patients thrive on parenteral nutrition.

Telehealth and Telemedicine Market worth $285.7 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, March 10, 2022
Ageing, Telecommunication, Dialysis, Physician, Risk, Telehealth, Teleradiology, Adoption, Health, Conditional sentence, Hospital, Prevalence, Bed, Patient, Social media, Solution, Technology, Software, Population, COVID-19, Region, Fraud, Overalls, CAGR, Awareness, Radiology, Infusion therapy, Pharmaceutical industry, Medical device, Cancer, Growth, Hospice, Diabetes

By component, the software and services segment took the largest share of the telehealth and telemedicine market in 2021.

Key Points: 
  • By component, the software and services segment took the largest share of the telehealth and telemedicine market in 2021.
  • Teleradiology segment commanded the largest share of the telehealth and telemedicine market, by application, in 2021.
  • Providers segment accounted for the largest end user segment of the telehealth and telemedicine market.
  • North America is expected to dominate the telehealth and telemedicine market during the forecast period.

Telehealth and Telemedicine Market worth $285.7 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, March 10, 2022
Ageing, Telecommunication, Dialysis, Physician, Risk, Telehealth, Teleradiology, Adoption, Health, Conditional sentence, Hospital, Prevalence, Bed, Patient, Social media, Solution, Technology, Software, Population, COVID-19, Region, Fraud, Overalls, CAGR, Awareness, Radiology, Infusion therapy, Pharmaceutical industry, Medical device, Cancer, Growth, Hospice, Diabetes

By component, the software and services segment took the largest share of the telehealth and telemedicine market in 2021.

Key Points: 
  • By component, the software and services segment took the largest share of the telehealth and telemedicine market in 2021.
  • Teleradiology segment commanded the largest share of the telehealth and telemedicine market, by application, in 2021.
  • Providers segment accounted for the largest end user segment of the telehealth and telemedicine market.
  • North America is expected to dominate the telehealth and telemedicine market during the forecast period.

PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021

Retrieved on: 
Wednesday, November 3, 2021
Oncology, Health, Medical Devices, Surgery, Other Health, General Health, Biotechnology, Carpal tunnel syndrome, Infusion therapy, Research, LinkedIn, Cancer, Laboratory developed test, LDT, Twitter, Security (finance), U.S. Securities and Exchange Commission, Patient, FDA, YouTube, Communication, Risk, Time, Conference, Annual report, Forward-looking statement, Company, Webcast, Intention, COVID-19, Infusion, Nasdaq, Therapy, GI, GERD, Pharmaceutical industry, Medical imaging

In addition, Dennis McGrath, the companies Chief Financial Officer, will discuss the companies third quarter 2021 financial results.

Key Points: 
  • In addition, Dennis McGrath, the companies Chief Financial Officer, will discuss the companies third quarter 2021 financial results.
  • All listeners should provide the operator with the conference call name PAVmed, Inc. Business Update Conference Call to join.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
  • Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Veris Health Showcased in PAVmed Digital Health Virtual Investor Event

Retrieved on: 
Friday, October 29, 2021
Biotechnology, Practice Management, Technology, Other Health, Health, General Health, Other Science, Other Technology, Medical Devices, Research, Science, Carpal tunnel syndrome, MD, Infusion therapy, Immunotherapy, Research, Director, LinkedIn, Microsoft, Cancer, Workflow, Twitter, Security (finance), U.S. Securities and Exchange Commission, Patient, FDA, YouTube, Digital health, Communication, Risk, Time, Data Analytics Acceleration Library, Annual report, Software, Forward-looking statement, Instagram, Company, Intention, CEO, Facebook, COVID-19, Growth, Infusion, IOT, Hospital, Health, GI, Physician, Risk management, Medical imaging

Veris, a majority-owned subsidiary of PAVmed, acquired Oncodisc Inc., a digital health company with groundbreaking tools to improve personalized cancer care in May 2021.

Key Points: 
  • Veris, a majority-owned subsidiary of PAVmed, acquired Oncodisc Inc., a digital health company with groundbreaking tools to improve personalized cancer care in May 2021.
  • Wireless communication to the patients smartphone and Veris cloud-based digital healthcare platform will deliver actionable real time data to patients and physicians efficiently and effectively.
  • Veris is targeting FDA 510(k) clearance of the intelligent implantable vascular access port and launch of the remote digital healthcare platform for H2-2022.
  • Im certain that Veris has the right approachto build an integrated digital health care platform that will help millions of cancer patients and their oncologists.

PAVmed Acquires EsophaCap Manufacturer CapNostics LLC

Company, Twitter, European, Forward-looking statement, Facebook, Risk, LLC, Intention, COVID-19, Infusion therapy, U.S. FDA, Academic health science centre, GLOBE, Time, LinkedIn, Cancer, Annual report, Instagram, FDA, U.S. Securities and Exchange Commission, Infusion, Communication, YouTube, Security (finance), GI, Carpal tunnel syndrome, Gastroesophageal reflux disease, Esophageal disease, Patient, Research, Nasdaq, Biomarker, Medical imaging, Risk management

Von Dyck, as well as an exclusive long-term manufacturing agreement with the EsophaCap contract manufacturer.

Key Points: 
  • Von Dyck, as well as an exclusive long-term manufacturing agreement with the EsophaCap contract manufacturer.
  • PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities.
  • For more information, please visit www.pavmed.com , follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube.
  • PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products.

PAVmed Acquires EsophaCap Manufacturer CapNostics LLC

Retrieved on: 
Thursday, October 7, 2021
Technology, Research, Medical Devices, Other Technology, Biotechnology, Health, Other Science, Science, Oncology, Company, Twitter, European, Forward-looking statement, Facebook, Risk, LLC, Intention, COVID-19, Infusion therapy, U.S. FDA, Academic health science centre, Time, LinkedIn, Cancer, Annual report, Instagram, FDA, U.S. Securities and Exchange Commission, Infusion, Communication, YouTube, Security (finance), GI, Carpal tunnel syndrome, Gastroesophageal reflux disease, Esophageal disease, Patient, Research, Nasdaq, Biomarker, Medical imaging, Risk management

Von Dyck, as well as an exclusive long-term manufacturing agreement with the EsophaCap contract manufacturer.

Key Points: 
  • Von Dyck, as well as an exclusive long-term manufacturing agreement with the EsophaCap contract manufacturer.
  • PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities.
  • For more information, please visit www.pavmed.com , follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube.
  • PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products.